Verastem, GenFleet to Advance New Programs Targeting RAS Pathway-Driven Cancers

 Synergistic Collaboration Based on Strengths of Verastem Oncology’s Pipeline and Development Expertise and GenFleet Therapeutics’ Discovery Capabilities

Exclusive Option for Verastem Oncology to License Up to Three Programs with Development and Commercialization Rights Outside China

https://www.biospace.com/article/releases/verastem-oncology-enters-discovery-and-development-collaboration-with-genfleet-therapeutics-to-advance-new-programs-targeting-ras-pathway-driven-cancers/